Status:
NOT_YET_RECRUITING
The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
Depressed
Bariatric Surgery
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infu...
Eligibility Criteria
Inclusion
- Age ≥18 years old and \<65 years old
- Patients with a BMI greater than 35 kg/m\^2
- Hamilton Depression score ≥7 points
- Planned to undergo elective laparoscopic sleeve gastrectomy
Exclusion
- ASA ≥ grade IV
- Those who have had or are currently suffering from mental disorders other than anxiety and depression, such as schizophrenia, bipolar disorder, organic mental disorders, etc.
- Those who are unable to cooperate in completing the scale assessment
- Have received ketamine/esketamine treatment, or are allergic to ketamine/esketamine
- Clarify ischemic cardiomyopathy or severe liver and kidney dysfunction (Child pugh grade C, CKD stage G5)
- People with opioid dependence and those who have been taking various types of painkillers for a long time (more than 3 months)
- Participate in other research
Key Trial Info
Start Date :
September 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 10 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT07179913
Start Date
September 10 2025
End Date
September 10 2026
Last Update
September 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.